Related Experiment Videos
Course of treated juvenile dermatomyositis
The Journal of Pediatrics
|September 1, 1984
Summary
Juvenile dermatomyositis (JDMS) shows varied clinical courses, including monocyclic, polycyclic, and chronic continuous patterns. Corticosteroid therapy improves prognosis, but understanding disease variability is key for optimal patient treatment.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Dermatology
Background:
- Juvenile dermatomyositis (JDMS) is a rare autoimmune disease affecting children.
- Previous observations suggested three clinical courses: monocyclic, polycyclic, and chronic continuous.
Purpose of the Study:
- To review the clinical courses and outcomes of patients with juvenile dermatomyositis.
- To evaluate the impact of corticosteroid therapy on JDMS prognosis.
- To understand the clinical variability of JDMS for tailored treatment strategies.
Main Methods:
- Retrospective review of medical records of 32 patients meeting study criteria.
- Observation period from 1960 to 1982 at Children's Hospital of Los Angeles.
- Categorization of JDMS clinical courses into monocyclic, chronic polycyclic, and chronic continuous.
Main Results:
- Monocyclic JDMS observed in 8 children, chronic polycyclic in 10, and chronic continuous in 14.
- 25 patients achieved remission without medication; one had mild JDMS without corticosteroids.
- Four patients had active JDMS despite therapy, with one severely handicapped; two patients died.
Conclusions:
- Corticosteroid therapy is associated with an improved prognosis for juvenile dermatomyositis.
- Significant clinical variability exists in JDMS, necessitating individualized treatment approaches.
- Further research into JDMS pathogenesis and treatment optimization is crucial for severe cases.